How to Scale Medical Device Registration Across 19 Latin American Markets

Registering a device in one Latin American market is a project. Registering in 19 is an operating system. The system breaks when a US or EU manufacturer treats each country as a local-distributor errand: a different titular in Mexico, a different detentor in Brazil, a different titular in Colombia, a droguería that also sells the catalog in Peru. Six months later the certificates exist and the manufacturer does not control them.

I am Julio Martinez-Clark, CEO of bioaccess®. This is the operator brief for teams that already have FDA clearance, approval, or a CE mark, and need sanitary registration across Latin America without converting the license into the distributor’s hostage. The public product is the LATAM Launch Subscription at USD 7,500 per year per country for the first device family — the card approved and published on 23 August 2026. Coverage is 19 markets. Six core desks sit on that page: ANVISA, INVIMA, COFEPRIS, ANMAT, ISP, DIGEMID.

The distributor-as-holder trap

Every Latin American regulator ties a device registration to an in-country legal entity. That entity is the titular, detentor, representante autorizado, or registration holder. On it sit tecnovigilancia, answers to the authority, variations, and — in several markets — importation. The distributor is a different function: sells, invoices, services. When the two functions sit in the same company, you do not have a channel. You have a partner who also owns the regulatory asset. Changing the partner means cesión de derechos, a new registro, or both.

That is how the instruments are written:

• Mexico (COFEPRIS). The named titular on the Registro Sanitario is the sanitary face of the product. A Mexico Registration Holder can name several distributors and importers on one certificate — which is why an independent holder is useful and a distributor-titular is expensive to unwind. As of 20 August 2026 you can check the named titular on the public Visor de Registros Sanitarios de Dispositivos Médicos (COFEPRIS Comunicado 21/2026). If your Mexican distributor is the name the visor shows, channel termination does not move the certificate.
• Brazil (ANVISA). RDC No. 751 of 15 September 2022 names a single detentor de registro. The foreign manufacturer cannot be that detentor. RDC 270/2019 lets the detentor authorize several importers without re-registering the device. A Brazil Registration Holder that is not the exclusive importer is the correct design.
• Colombia (INVIMA). Decreto 4725 of 2005 is the sanitary-registration statute. INVIMA contemplates one titular with several importers. The manufacturer does not have to hand titularidad to the first commercializer.
• Peru (DIGEMID). The titular must be an authorized pharmaceutical establishment, typically a droguería, under Ley N° 29459 and Decreto Supremo N° 016-2011-SA. Decreto Supremo N° 001-2024-SA lets an independent Peru Registration Holder sit apart from the distributor; other droguerías can obtain their own CRS to import a product already registered by another titular. The live Peru DIGEMID page already states that model.
• Argentina (ANMAT). One authorized representative per registro; that representative is titular and importer. Disposición 2318/2002 was replaced by Disposición 64/2025. Changing AAR usually means registering again. The same single-representative logic applies in Ecuador (Resolución ARCSA-DE-026-2016-YMIH, as amended by ARCSA-DE-2023-033-AKRG), El Salvador (SRS), Panama (Ley 90 of 2017 and Decreto Ejecutivo No. 490 of 4 October 2019), and DIGEMAPS in the Dominican Republic.

bioaccess® holds registrations through its own local entities for the manufacturer’s benefit, with defined transfer provisions in the agreement. Importer rules: LATAM importer-of-record guide.

Classification logic diverges — ANVISA, COFEPRIS, INVIMA, DIGEMID

US regulatory affairs teams still paste a single “Class II” onto a 19-country tracker. That is how dossiers bounce. Four large desks do not share a classification statute, a class count, or a review regime. A device that is Class II at FDA can be Class III at COFEPRIS because it stays in the body more than 30 days, Class III at ANVISA because it is a long-term implant, Class IIb at INVIMA, and Class III or IV at DIGEMID. Classify in each rule set. Do not infer.

Brazil — ANVISA, four classes, two regimes. RDC 751/2022 Article 5: Class I low, II medium, III high, IV maximum risk, using 22 rules in Annex I. Articles 6–7: Classes I and II go to notificação; Classes III and IV go to registro, with statutory maximums up to about 250 days (equipment), 320 days (materials), and 365 days (IVDs). Implantable and long-term surgically invasive devices default to Class III unless a specific rule says otherwise. A US 510(k) orthopedic implant does not automatically enter Brazilian notificação.

Mexico — COFEPRIS, three classes, duration-and-novelty logic. Reglamento de Insumos para la Salud, Article 83: Class I — known in medical practice, generally not introduced into the body; Class II — known in practice, generally introduced and remaining fewer than 30 days; Class III — new or recently accepted, or introduced and remaining more than 30 days. That last “or” is the trap for biomaterials and implants. The equivalence route (vía abreviada) is for devices already approved and marketed by the same manufacturer in a reference country (US FDA, Health Canada, or Japan). A CE mark alone does not qualify. Standard response times on the market-access page: about 30 / 35 / 60 working days by class I / II / III.

Colombia — INVIMA, four classes with a IIa/IIb split. Decreto 4725 of 2005, Article 5: Class I low risk, IIa moderate (special controls in manufacture), IIb high (special controls in design and manufacture), III very high risk. Class I and IIa receive registro sanitario automático. Class IIb and III undergo full prior review on the order of ~90 business days. A US “Class II” memo has to land on IIa or IIb; that choice is automatic issuance versus a 90-business-day file.

Peru — DIGEMID, four classes, separate classification regulation. Decreto Supremo N° 003-2020-SA sets classification rules and essential principles of safety and performance: Class I low, II moderate, III high, IV critical. Registration, control, and vigilance remain Decreto Supremo N° 016-2011-SA (as amended, including Decreto Supremo N° 011-2022-SA), under Ley N° 29459. DIGEMID’s device page points at Articles 124–127 for requirements by risk level. Imports run through a licensed droguería. Do not treat a Colombian Class IIa decision as a Peruvian Class II decision.

Chile (ISP), Argentina (ANMAT, Classes I–IV), Panama (GHTF/IMDRF under Ley 90 / Decreto 490), and the rest of the 19-market list add more logic, not less. The operating move is a classification matrix: one row per SKU, one column per authority, intended-purpose sentence, rule, class, regime. If those cells disagree with the US product-code memo, the US memo loses.

Consolidate independent in-country authorized representation

The alternative to 19 distributor-holders is one doctrine of local authorized representation (LAR) / registration holder, executed through dedicated in-country entities that do not sell the device. Lock these five roles per country before anyone signs a distribution LOI:

1. Who is the titular / detentor / AAR / PRH. A manufacturer branch, an independent professional holder, or the distributor. Pick one on purpose. Independent holder is the default that keeps the certificate movable.
2. Who may import. One IOR (Argentina, Panama, many single-representative markets) versus several importers on one registro (Mexico, Colombia, Brazil under RDC 270/2019, Peru via additional CRS). Write the commercial contract to the sanitary fact, not the other way around.
3. Who files tecnovigilancia and field actions. In Mexico, Brazil, and Colombia the local holder must run a named system after the certificate is granted (Ley General de Salud art. 262 Bis and NOM-240-SSA1-2012 §6.7.12; RDC 67/2009 art. 3; Resolución 4816/2008). If that system fails, the registro can be suspended or cancelled.
4. Who owns variations. Model adds, software bumps, sterile-barrier changes. Quiet EU updates do not auto-propagate into COFEPRIS, ANVISA, INVIMA, or DIGEMID.
5. Who holds the translation memory. Certified Spanish or Portuguese of IFU, labels, and technical file — sworn where Brazil and Argentina require it. If a distributor commissions the translation, they hold the glossary you will need at renewal.

bioaccess®’s published structure is that independent holder, through our own local entities, across the 19-market footprint. We register FDA-cleared (510(k)) or approved (PMA), or CE-marked, devices. We do not obtain FDA clearance or CE marking on your behalf. As of the July 2026 market-access card: 25+ device registrations completed; 25+ active registrations held through bioaccess®’s own in-country entities; 15+ years on COFEPRIS, INVIMA, ANVISA, and ANMAT. Figures are self-reported. If the commercial plan is one country and a local holder with its own entity is enough, that product is valid. If the plan is several certificates under the same transfer doctrine, stop hiring a new local agent per capital.

Flat-subscription maintenance versus one-off consulting fees

One-off RA consulting sells a dossier. The certificate then sits with whoever filed it, and every variation, renewal, and adverse-event clock is a new statement of work. That is how a 19-country plan becomes 19 uncoordinated invoices.

The public LATAM Launch Subscription / Market Access Essentials card is a different SKU: USD 7,500 per year per country for the first device family — all models, references, and variants within that family, as defined in the agreement. Additional families are quoted on request. Mexico Class III / energy is USD 10,000/year; Brazil Class III/IV is USD 12,000/year plus INMETRO pass-through; Class IIb Professional is about USD 15,000/year. Multi-country discounts: 10% off at 3+ countries, 15% off at 5+ countries. Trial-to-Market Bridge: 20% off for bioaccess® clinical-trial clients.

Included on the USD 7,500 card: government submission fees; certified Spanish/Portuguese translation of IFU, labels, and technical file (sworn where Brazil and Argentina require it), with the translation memory the manufacturer’s property; in-country titular / holder / importer of record; post-approval modifications, agency liaison, and tecnovigilancia as holder.

Outside the flat fee: Brazil BGMP manufacturing-site audit (about USD 13,500/site), INMETRO, ANATEL, and telecom/EMC + RF homologation for wireless devices — billed at vendor cost + 20% G&A. Those telecom filings run through IFT, ANATEL, ENACOM, SUBTEL, or CRC, not the health authority. Importer-of-record logistics: 20% of CIF per shipment (USD 0 if no import).

Typical competitor unbundling already published on the market-access page: government fees USD 1,500–5,000 per country; translations USD 4,000–15,000; registered agent USD 3,000–5,000 per year; liaison USD 500–2,000 per month. Global RA consultancies typically quote USD 15,000–30,000 per country for registration alone. Pure Global’s published Mexico/Brazil sticker is USD 2,000–3,000 for dossier + holder (PR Newswire, 5 February 2026) — a different SKU, with no published tecnovigilancia price. USD 7,500 is the holder who runs the vigilance system that keeps the registro alive.

The bioaccess® Submission Guarantee covers what we control: complete dossier submitted, in certified Spanish or Portuguese, with government fees paid, on the committed schedule — or a credit of a portion of that country’s annual fee. Full terms in the proposal. Agency queries pause any statutory period. Typical time-to-registration once the dossier is in: 90 days for low-risk devices and 120 days for Class II/III, varying by country and class.

Build the system, then pick the first three countries

1. Write the intended-purpose sentence in Spanish and Portuguese. If the team cannot agree on one sentence, stop. Classification will not survive three agencies.
2. Fill the classification matrix for ANVISA, COFEPRIS, INVIMA, and DIGEMID — then the remaining markets on the launch list. Record the rule, the class, and the regime.
3. Name the independent holder per country before any distribution LOI. Confirm, in Mexico, that the visor will show that name once the registro is vigente.
4. Separate the first-in-human file if you still need patients. Trial authorization and commercial registro are different desks. We still run first-in-human work in Colombia when the device, sites, and file fit — that is not a reason to hand INVIMA titularidad to a distributor.
5. Put maintenance on a flat annual subscription so variations, renewals, and tecnovigilancia are not a new consulting event.

Learn about the bioaccess® LATAM Launch Subscription at bioaccessla.com/market-access. Country pages for ANVISA, COFEPRIS, INVIMA, ANMAT, ISP, DIGEMID, and MINSA sit under that hub. Importer rules: LATAM importer of record.